0.9783
price up icon1.91%   0.0183
 
loading
Jaguar Health Inc stock is traded at $0.9783, with a volume of 107.01K. It is up +1.91% in the last 24 hours and down -19.81% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.96
Open:
$0.9942
24h Volume:
107.01K
Relative Volume:
0.38
Market Cap:
$8.87M
Revenue:
$10.72M
Net Income/Loss:
$-39.71M
P/E Ratio:
-0.0629
EPS:
-15.5542
Net Cash Flow:
$-32.21M
1W Performance:
+6.34%
1M Performance:
-19.81%
6M Performance:
-93.69%
1Y Performance:
-95.99%
1-Day Range:
Value
$0.97
$1.00
1-Week Range:
Value
$0.9325
$1.20
52-Week Range:
Value
$0.90
$30.86

Jaguar Health Inc Stock (JAGX) Company Profile

Name
Name
Jaguar Health Inc
Name
Phone
415-371-8300
Name
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Name
Employee
49
Name
Twitter
@Jaguar_Health
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
JAGX 0.9783 8.87M 10.72M -39.71M -32.21M -15.55
VRTX 467.20 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.66 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.96 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.32 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.33 24.08B 3.30B -501.07M 1.03B 11.54

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-07-21 Initiated Cantor Fitzgerald Overweight
Jul-11-17 Initiated Rodman & Renshaw Buy

Jaguar Health Inc Stock (JAGX) Latest News

pulisher
Nov 16, 2024

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 16, 2024
pulisher
Nov 16, 2024

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024
pulisher
Nov 14, 2024

Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Jaguar Health extends agreement with financial managers - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Jaguar Health Sees Revenue Growth with New Product Launches - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Jaguar Health extends agreement with financial managers By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Jaguar Health Reports Third Quarter 2024 Financial Results - Yahoo Finance

Nov 13, 2024
pulisher
Nov 11, 2024

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Bluefield Daily Telegraph

Nov 11, 2024
pulisher
Nov 11, 2024

Jaguar Health (JAGX) Sets Q3 2024 Earnings Call: Key Financial Updates Coming | JAGX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 09, 2024

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27% - Simply Wall St

Nov 09, 2024
pulisher
Nov 09, 2024

Jaguar Health stock hits 52-week low at $0.93 amid challenges By Investing.com - Investing.com South Africa

Nov 09, 2024
pulisher
Nov 08, 2024

Jaguar Health stock hits 52-week low at $0.93 amid challenges - Investing.com India

Nov 08, 2024
pulisher
Nov 07, 2024

JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - Corsicana Daily Sun

Nov 06, 2024
pulisher
Nov 06, 2024

Jaguar Health Secures FDA Renewal for Breakthrough Canine Cancer Drug Through 2025 | JAGX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 04, 2024

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) - StockTitan

Nov 04, 2024
pulisher
Nov 02, 2024

JAGX (Jaguar Health) Total Inventories : $9.56 Mil (As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Oct 29, 2024

Jaguar Health reports promising crofelemer study results - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Jaguar Health reports promising crofelemer study results By Investing.com - Investing.com UK

Oct 29, 2024
pulisher
Oct 29, 2024

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual MeetingChannel3000.com - Channel3000.com - WISC-TV3

Oct 29, 2024
pulisher
Oct 26, 2024

Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN

Oct 26, 2024
pulisher
Oct 17, 2024

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. - BioSpace

Oct 17, 2024
pulisher
Oct 16, 2024

Small-cap biotech Jaguar Health’s stock jumps 7% as it launches treatment for oral mucositis in cancer patients - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Jaguar Health launches Gelclair for oral mucositis relief By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Jaguar Health’s stock jumps as it launches treatment for oral mucositis - MarketWatch

Oct 16, 2024
pulisher
Oct 16, 2024

Jaguar Health launches Gelclair for oral mucositis relief - Investing.com

Oct 16, 2024
pulisher
Oct 11, 2024

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - guardonline.com

Oct 11, 2024
pulisher
Oct 10, 2024

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum - Corsicana Daily Sun

Oct 10, 2024
pulisher
Oct 09, 2024

Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada

Oct 09, 2024
pulisher
Oct 08, 2024

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial - Joplin Globe

Oct 08, 2024
pulisher
Oct 02, 2024

Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup - Clinical Trials Arena

Oct 02, 2024
pulisher
Oct 01, 2024

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer - Corsicana Daily Sun

Oct 01, 2024
pulisher
Sep 26, 2024

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patien - AccessWire

Sep 26, 2024
pulisher
Sep 25, 2024

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - BioSpace

Sep 24, 2024
pulisher
Sep 24, 2024

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in... - Markets Insider

Sep 24, 2024
pulisher
Sep 16, 2024

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference - Weatherford Democrat

Sep 16, 2024

Jaguar Health Inc Stock (JAGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):